Search Results 491-500 of 16631 for alopecia

1. PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination with Anti-PD-1/L1 in Patients with Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Persistence of AEs from prior anti-cancer therapy that have not resolved to Grade 1 (except for alopecia and hypothyroidism), or any history of Grade ≥ 3 ...

2. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   Adverse events from prior anti-cancer therapy resolved to ≤Grade 1 (with the exception of alopecia and anorexia). Exclusion Criteria for Phase II Portion ...

3. A Study to Evaluate the Safety and Tolerability of DCC-2618 in Patients with Advanced Malignancies - Mayo Clinic

   Resolution of all toxicities from prior therapy to ≤ Grade 1 (or baseline) within 1 week prior to the first dose of study drug (excluding alopecia) and ...

4. A Study Of AL101 In Patients with Adenoid Cystic Carcinoma Bearing Activating Notch Mutations - Mayo Clinic

   0) ≤ Grade 1, except for sensory neuropathy with resolution to ≤ Grade 2 and alopecia. Male and/or Female: Contraceptive use by men or women should be ...

5. Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer - Mayo Clinic

   Residual CTCAE ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy. Known history of HIV ...

6. Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence - Mayo Clinic

   Patients with Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not ...

7. A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors - Mayo Clinic

   Toxic effects of prior anti-cancer therapy considered as chronic, such as chemotherapy-induced fatigue, alopecia, or anorexia of ≤ Grade 2, where no more ...

8. A Study to Evaluate Mutanome-directed Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   About this study. The purpose of this study is to evaluate the safety and tolerability of multiple subcutaneous injections of a mutanome-directed active ...

9. A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer - Mayo Clinic

   ... alopecia or toxicities that are stable and well-controlled and there is agreement to allow by the investigator and sponsor; Subject unable to receive both ...

10. Transforming Non-Invasive Liver Disease Detection by Magnetic Resonance Elastography - Mayo Clinic

    About this study. A variety of liver insults lead to pathological changes in liver architecture that culminate in cirrhosis. While invasive liver biopsy was ...